Oncolytics Biotech issued patent that covers methods for treating cell proliferative disorders

Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted its 35th U.S. Patent, # 7,731,951 entitled "Viruses for the Treatment of Cellular Proliferative Disorders." The patent claims cover methods for treating cell proliferative disorders by administering modified vaccinia virus to proliferating cells having an activated Ras-pathway.

"This patent provides further coverage with respect to the use of a range of modified viruses to treat a variety of different cancers," said Mary Ann Dillahunty, Vice President of Intellectual Property for Oncolytics.

Oncolytics now has issued patents that cover methods for treating proliferative disorders using modified adenovirus, HSV, parapoxvirus and vaccinia virus in addition to an extensive patent portfolio covering oncolytic reovirus.

Source:

Oncolytics Biotech Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
The structure dynamics of the SARS-CoV-2 genome in cells, cell lysates and virions